JAK2 and breast carcinoma: In these studies we also found ERBB2/HER2, a member of epidermal growth factor receptor family which is overexpressed in about 10% of the ER+ breast cancers [11, 12] phosphorylated and activated by JAK2 induced by PRL through PRLR.